COMPANY

Neuraptive Therapeutics

HQ: Chesterbrook, PA source · neuraptive.com ↗

Location: Chesterbrook, PA · source · Oct 12, 2026

Profile checked Oct 10, 2026

Keywords: Peripheral Nerve Injury Upper Limb Peripheral Nerve Injury Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves Peripheral Nerve Injuries Facial Paralysis NTX-001 NTX-001 (PEG-Fusion)

4Trials (company is sponsor)

Timeline

Feb 10, 2025 Trial start Phase 3: This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations. source ↗
Jul 12, 2022 Trial start Phase 2: A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair. source ↗
Sep 25, 2020 Trial start Phase 2: Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries source ↗

Upcoming milestones

Mar 31, 2027 (ESTIMATED) · Phase 3 · This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations. · NCT06616025

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06616025	This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.	Phase 3	Recruiting	Feb 10, 2025	Mar 31, 2027 (estimated)
NCT05565846	NTX-001 to Repair Peripheral Nerve Transection(s)	Not listed	Available	Not listed	Not listed
NCT04572906	Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries	Phase 2	Completed	Sep 25, 2020	Jun 27, 2024 (actual)
NCT05293522	A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.	Phase 2	Terminated	Jul 12, 2022	Aug 22, 2023 (actual)